Literature DB >> 27813540

Protective effects of Angelica sinensis polysaccharide against hyperglycemia and liver injury in multiple low-dose streptozotocin-induced type 2 diabetic BALB/c mice.

Kaiping Wang1, Zhuohong Tang1, Ziming Zheng2, Peng Cao1, Weizhi Shui1, Qiang Li2, Yu Zhang2.   

Abstract

Angelica sinensis polysaccharide (ASP), one of the major active ingredients isolated from the roots of Angelica sinensis (Oliv.) Diels, possesses numerous bioactivities. The aim of the present study was to explore the mechanisms of ASP-mediated hypoglycemic effects in type 2 diabetic BALB/c mice induced by multiple low-dose streptozotocin (STZ) injections plus a long-term high-fat diet (HFD) feeding. The potential mechanism explicating the hepatoprotective effect was also considered. Specifically, serum and hepatic biochemical parameters were determined, as well as the key proteins involved in glucose metabolism and apoptosis. The multiple low-dose STZ injection plus HFD treatment induced significant hyperglycemia, hyperlipidemia and marked liver injury. Our results showed that ASP had beneficial effects in preventing hyperglycemia, stimulating insulin secretion, promoting hepatic glycogen synthesis, regulating adipokine release, reducing liver fat accumulation, and attenuating liver injury. Moreover, mechanistic studies illustrated that ASP could upregulate the expression of PPARγ and liver insulin signaling proteins, including IRS-2, PI3K, Akt, p-Akt and GLUT2, increase anti-apoptotic protein Bcl-2, decrease pro-apoptotic protein Bax expressions, and protect the mice against hepatic damage. These findings revealed the potential mechanisms of ASP-mediated therapeutic effects in diabetic mice. It suggested that ASP might be used in prescriptions or functional foods for the prevention or treatment of diabetes and liver diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27813540     DOI: 10.1039/c6fo01196a

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  6 in total

1.  Network pharmacology-based identification of major component of Angelica sinensis and its action mechanism for the treatment of acute myocardial infarction.

Authors:  Xiaowei Niu; Jingjing Zhang; Jinrong Ni; Runqing Wang; Weiqiang Zhang; Shaobo Sun; Yu Peng; Ming Bai; Zheng Zhang
Journal:  Biosci Rep       Date:  2018-11-07       Impact factor: 3.840

Review 2.  Advances in Mechanism Research on Polygonatum in Prevention and Treatment of Diabetes.

Authors:  Shuang Liu; Qiao-Jun Jia; Yi-Qing Peng; Ting-Hui Feng; Shu-Ting Hu; Juan-E Dong; Zong-Suo Liang
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

3.  Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice.

Authors:  Yu Zhang; Yufeng Li; Junjun Zhao; Cong Wang; Bin Deng; Qilin Zhang; Chen Shi
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

4.  Effect of crude polysaccharide from seaweed, Dictyopteris divaricata (CDDP) on gut microbiota restoration and anti-diabetic activity in streptozotocin (STZ)-induced T1DM mice.

Authors:  Nimra Zafar Siddiqui; Ata Ur Rehman; Waleed Yousuf; Asif Iqbal Khan; Nabeel Ahmed Farooqui; Shizhu Zang; Yi Xin; Liang Wang
Journal:  Gut Pathog       Date:  2022-09-17       Impact factor: 5.324

5.  An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies.

Authors:  Min-Han Chi; Jung Chao; Chien-Yu Ko; Shyh-Shyun Huang
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

6.  Inhibition of Osteoarthritis-Related Molecules by Isomucronulatol 7-O-β-d-glucoside and Ecliptasaponin A in IL-1β-Stimulated Chondrosarcoma Cell Model.

Authors:  Gwan Ui Hong; Jung-Yun Lee; Hanna Kang; Tae Yang Kim; Jae Yeo Park; Eun Young Hong; Youn Ho Shin; Sung Hoon Jung; Hung-Bae Chang; Young Ho Kim; Young-In Kwon; Jai Youl Ro
Journal:  Molecules       Date:  2018-10-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.